Vaginitis
Drug research and approvals for vaginitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 31 studies of vaginitis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 31
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting now
Newest start dates first, of 31 recruiting on ClinicalTrials.gov ↗- A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability,…NCT07663838 · Phase 1 · Changchun GeneScience Pharmaceutical Co., Ltd. · starts Aug 15, 2026
- Improving Maternal and Child Health Through Point-of-care STI TestingNCT07290439 · Not applicable · Emory University · starts Aug 11, 2026
- F-GYN for Vaginal Dryness and Vulvovaginal AtrophyNCT07701863 · Not applicable · Biovico Sp. z o.o. · starts Jul 24, 2026
- Biweekly Long-term Occidiofungin Study for Suppression of Mycotic RecurrenceNCT07521137 · Phase 2 · Sano Chemicals Inc · starts Jun 4, 2026
- Large Algorithm Setting and Validation StudyNCT07607470 · Not reported · Nanopath, Inc · starts Jun 3, 2026
- Evaluation of the Efficacy of a Probiotic Product as an Adjuvant Treatment for Vulvovaginal CandidiasisNCT07603895 · Not applicable · Bioithas SL · starts May 25, 2026
- The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility StudyNCT05434104 · Not applicable · Guy's and St Thomas' NHS Foundation Trust · starts Apr 16, 2026
- Impact of Internal Menstrual Protections on Immunity and Vaginal MicrobiotaNCT07199998 · Not reported · Centre National de la Recherche Scientifique, France · starts Apr 7, 2026
- Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment TrialNCT07481955 · Phase 2 · Freya Biosciences ApS · starts Mar 23, 2026
- Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial VaginosisNCT07474831 · Not applicable · Liaquat University of Medical & Health Sciences · starts Mar 23, 2026
Drug pipeline
Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indicationsApproved 3
- IbuprofenCyclooxygenase inhibitor
- NaproxenCyclooxygenase inhibitor
- BenzydamineCyclooxygenase inhibitor
Phase 3 6
- MetronidazoleDNA inhibitor
- FluconazoleCytochrome P450 51 inhibitor
- Clindamycin phosphateBacterial 70S ribosome inhibitor
- TinidazoleDNA disrupting agent
- ClotrimazoleCytochrome P450 51 inhibitor
- ButoconazoleCytochrome P450 51 inhibitor
Phase 2 2
Phase 1 or earlier 1
- TerconazoleCytochrome P450 51 inhibitor
How its trials ended
113 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 16 whose ending is known, 69% met their primary endpoint, 0% missed it and 31% stopped early.
- Completed, result not reported5952%
- Ongoing2018%
- Status unknown1816%
- Met its primary endpoint1110%
- Stopped: other or unclear44%
- Stopped: funding11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA